Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 215 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Non-Alcoholic Steatohepatitis - Pipeline Review, H1 2015', provides an overview of the Non-Alcoholic Steatohepatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Non-Alcoholic Steatohepatitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Non-Alcoholic Steatohepatitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Non-Alcoholic Steatohepatitis Overview 8
Therapeutics Development 9
Pipeline Products for Non-Alcoholic Steatohepatitis - Overview 9
Pipeline Products for Non-Alcoholic Steatohepatitis - Comparative Analysis 10
Non-Alcoholic Steatohepatitis - Therapeutics under Development by Companies 11
Non-Alcoholic Steatohepatitis - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Non-Alcoholic Steatohepatitis - Products under Development by Companies 17
Non-Alcoholic Steatohepatitis - Companies Involved in Therapeutics Development 21
Cardax Pharmaceuticals, Inc. 21
Conatus Pharmaceuticals Inc. 22
Connexios Life Sciences Pvt. Ltd. 23
Cubist Pharmaceuticals, Inc. 24
Daiichi Sankyo Company, Limited 25
Dr. Falk Pharma GmbH 26
Dynavax Technologies Corporation 27
Galectin Therapeutics, Inc. 28
Galmed International Ltd. 29
Genfit SA 30
Gilead Sciences, Inc. 31
Immuron Limited 32
Intercept Pharmaceuticals, Inc. 33
Isis Pharmaceuticals, Inc. 34
Jenrin Discovery, Inc. 35
Kadmon Corporation, LLC 36
Kissei Pharmaceutical Co., Ltd. 37
Kyorin Pharmaceutical Co., Ltd. 38
La Jolla Pharmaceutical Company 39
Mochida Pharmaceutical Co., Ltd. 40
Novo Nordisk A/S 41
Pharmaxis Limited 42
Phenex Pharmaceuticals AG 43
ProMetic Life Sciences Inc. 44
Raptor Pharmaceuticals Corp. 45
Shire Plc 46
Stelic Institute & Co. 47
Tobira Therapeutics, Inc. 48
Verva Pharmaceuticals Limited 49
Wellstat Therapeutics Corporation 50
Zafgen Inc. 51
Zydus Cadila Healthcare Limited 52
Non-Alcoholic Steatohepatitis - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Target 54
Assessment by Mechanism of Action 57
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
AM-0010 - Drug Profile 64
Aramchol - Drug Profile 65
CDX-085 - Drug Profile 67
cenicriviroc - Drug Profile 69
CNX-014 - Drug Profile 71
CNX-023 - Drug Profile 72
CNX-024 - Drug Profile 73
CNX-025 - Drug Profile 74
cysteamine DR - Drug Profile 75
DV-1179 - Drug Profile 78
emricasan - Drug Profile 80
GCS-100 - Drug Profile 82
GFT-505 - Drug Profile 84
GR-MD-02 - Drug Profile 87
icosapent ethyl - Drug Profile 89
IMM-124E - Drug Profile 90
ISIS-DGAT2Rx - Drug Profile 92
JD-5037 - Drug Profile 93
JKB-119 - Drug Profile 94
JKB-121 - Drug Profile 95
KD-025 - Drug Profile 96
liraglutide (recombinant) - Drug Profile 98
LJPC-1010 - Drug Profile 101
MAT-8800 - Drug Profile 102
methazolamide - Drug Profile 103
MGL-3196 - Drug Profile 104
Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases - Drug Profile 106
ND-630 - Drug Profile 108
ND-654 - Drug Profile 109
norursodeoxycholic acid - Drug Profile 110
obeticholic acid - Drug Profile 111
PBI-4050 - Drug Profile 114
PN-2XXX - Drug Profile 115
Px-102 - Drug Profile 116
Px-103 - Drug Profile 117
PXS-4728A - Drug Profile 118
PZ-235 - Drug Profile 119
remogliflozin etabonate - Drug Profile 120
saroglitazar - Drug Profile 123
SHP-626 - Drug Profile 124
simtuzumab - Drug Profile 125
Small Molecule for Non-Alcoholic Steatohepatitis - Drug Profile 127
Small Molecule to Inhibit SCD-1 for Nonalcoholic Steatohepatitis - Drug Profile 128
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile 129
Small Molecules to Inhibit ACC for Metabolic Disorders - Drug Profile 130
solithromycin - Drug Profile 131
STNM-09 - Drug Profile 133
TGFTX-3 Program - Drug Profile 134
tipelukast - Drug Profile 135
TRX-318 - Drug Profile 137
VK-0214 - Drug Profile 138
VVP-100-X - Drug Profile 139
ZGN-839 - Drug Profile 140
Non-Alcoholic Steatohepatitis - Recent Pipeline Updates 141
Non-Alcoholic Steatohepatitis - Dormant Projects 199
Non-Alcoholic Steatohepatitis - Discontinued Products 201
Non-Alcoholic Steatohepatitis - Product Development Milestones 202
Featured News & Press Releases 202
Appendix 210
Methodology 210
Coverage 210
Secondary Research 210
Primary Research 210
Expert Panel Validation 210
Contact Us 211
Disclaimer 211

List of Tables
Number of Products under Development for Non-Alcoholic Steatohepatitis, H1 2015 13
Number of Products under Development for Non-Alcoholic Steatohepatitis - Comparative Analysis, H1 2015 14
Number of Products under Development by Companies, H1 2015 16
Number of Products under Development by Companies, H1 2015 (Contd..1) 17
Number of Products under Development by Companies, H1 2015 (Contd..2) 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Products under Development by Companies, H1 2015 21
Products under Development by Companies, H1 2015 (Contd..1) 22
Products under Development by Companies, H1 2015 (Contd..2) 23
Products under Development by Companies, H1 2015 (Contd..3) 24
Non-Alcoholic Steatohepatitis - Pipeline by Cardax Pharmaceuticals, Inc., H1 2015 25
Non-Alcoholic Steatohepatitis - Pipeline by Conatus Pharmaceuticals Inc., H1 2015 26
Non-Alcoholic Steatohepatitis - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2015 27
Non-Alcoholic Steatohepatitis - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 28
Non-Alcoholic Steatohepatitis - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 29
Non-Alcoholic Steatohepatitis - Pipeline by Dr. Falk Pharma GmbH, H1 2015 30
Non-Alcoholic Steatohepatitis - Pipeline by Dynavax Technologies Corporation, H1 2015 31
Non-Alcoholic Steatohepatitis - Pipeline by Galectin Therapeutics, Inc., H1 2015 32
Non-Alcoholic Steatohepatitis - Pipeline by Galmed International Ltd., H1 2015 33
Non-Alcoholic Steatohepatitis - Pipeline by Genfit SA, H1 2015 34
Non-Alcoholic Steatohepatitis - Pipeline by Gilead Sciences, Inc., H1 2015 35
Non-Alcoholic Steatohepatitis - Pipeline by Immuron Limited, H1 2015 36
Non-Alcoholic Steatohepatitis - Pipeline by Intercept Pharmaceuticals, Inc., H1 2015 37
Non-Alcoholic Steatohepatitis - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 38
Non-Alcoholic Steatohepatitis - Pipeline by Jenrin Discovery, Inc., H1 2015 39
Non-Alcoholic Steatohepatitis - Pipeline by Kadmon Corporation, LLC, H1 2015 40
Non-Alcoholic Steatohepatitis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 41
Non-Alcoholic Steatohepatitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 42
Non-Alcoholic Steatohepatitis - Pipeline by La Jolla Pharmaceutical Company, H1 2015 43
Non-Alcoholic Steatohepatitis - Pipeline by Mochida Pharmaceutical Co., Ltd., H1 2015 44
Non-Alcoholic Steatohepatitis - Pipeline by Novo Nordisk A/S, H1 2015 45
Non-Alcoholic Steatohepatitis - Pipeline by Pharmaxis Limited, H1 2015 46
Non-Alcoholic Steatohepatitis - Pipeline by Phenex Pharmaceuticals AG, H1 2015 47
Non-Alcoholic Steatohepatitis - Pipeline by ProMetic Life Sciences Inc., H1 2015 48
Non-Alcoholic Steatohepatitis - Pipeline by Raptor Pharmaceuticals Corp., H1 2015 49
Non-Alcoholic Steatohepatitis - Pipeline by Shire Plc, H1 2015 50
Non-Alcoholic Steatohepatitis - Pipeline by Stelic Institute & Co., H1 2015 51
Non-Alcoholic Steatohepatitis - Pipeline by Tobira Therapeutics, Inc., H1 2015 52
Non-Alcoholic Steatohepatitis - Pipeline by Verva Pharmaceuticals Limited, H1 2015 53
Non-Alcoholic Steatohepatitis - Pipeline by Wellstat Therapeutics Corporation, H1 2015 54
Non-Alcoholic Steatohepatitis - Pipeline by Zafgen Inc., H1 2015 55
Non-Alcoholic Steatohepatitis - Pipeline by Zydus Cadila Healthcare Limited, H1 2015 56
Assessment by Monotherapy Products, H1 2015 57
Number of Products by Stage and Target, H1 2015 59
Number of Products by Stage and Mechanism of Action, H1 2015 62
Number of Products by Stage and Route of Administration, H1 2015 65
Number of Products by Stage and Molecule Type, H1 2015 67
Non-Alcoholic Steatohepatitis Therapeutics - Recent Pipeline Updates, H1 2015 145
Non-Alcoholic Steatohepatitis - Dormant Projects, H1 2015 203
Non-Alcoholic Steatohepatitis - Dormant Projects (Contd..1), H1 2015 204
Non-Alcoholic Steatohepatitis - Discontinued Products, H1 2015 205